-
There are new developments in the research and development of domestic children's drugs, and the drug company's innovative drug is approved for RPDD
Time of Update: 2021-12-30
In short, China's children's drug market is still in a situation where there are few special varieties, fewer suitable dosage forms, fewer manufacturers, and high attention from enterprises but low actual research and development enthusiasm .
-
The first domestically produced COVID-19 neutralizing antibody combination therapy was approved by the National Food and Drug Administration
Time of Update: 2021-12-30
It is reported that the State Food and Drug Administration, in accordance with the relevant provisions of the Drug Administration Law, in accordance with the special drug approval procedures, conducts emergency review and approval, and approves the above two drugs to be used in combination to treat mild and common types with progress to severe (including hospitalization or Death) Adults and adolescents (12-17 years old, weight ≥40kg) with high-risk factors, patients with novel coronavirus infection (COVID-19) .
-
Hutchison Medical's introduction of anti-tumor drug tazemetostat tablets for more than 300 million US dollars applies for clinical application in China
Time of Update: 2021-12-30
Screenshot source: CDE official websitePublic information shows that tazemetostat is a "first-in-class" EZH2 methyltransferase inhibitor developed by Epizyme.
In addition, tazemetostat is also being developed for the treatment of diffuse large B-cell lymphoma, prostate cancer and ovarian cancer .
-
Why doesn't the negotiation of medical insurance drugs directly show the low price?
Time of Update: 2021-12-30
On the one hand, for drugs that are eligible for negotiation, the medical insurance department organizes relevant companies to submit calculation data according to a unified template, which mainly includes: basic drug information, relevant safety, effectiveness, and economic information, intended prices, and corresponding evidence materials .
-
In the future, the development of my country's pharmaceutical industry will present three new trends
Time of Update: 2021-12-30
In recent years, as digitalization and intelligence have gradually become emerging forces in the transformation and upgrading of China's medical system, its integration and innovation with the pharmaceutical industry has also begun to become a new industry trend .
-
Daiichi Sankyo/AstraZeneca TROP-2 ADC releases latest data on triple-negative breast cancer cohort
Time of Update: 2021-12-30
On December 7, Daiichi Sankyo and AstraZeneca announced the TROP2 targeted antibody drug conjugate (ADC) datopotamab deruxtecan (Dato-DXd, DS-1062a) in the phase 1 trial of TROPION-PanTumor01 to treat triple-negative breast cancer (TNBC) latest data .
-
The indications for first-line treatment of Iris vometinib mesylate tablets are planned to be included in the priority review
Time of Update: 2021-12-30
On December 8, the latest announcement on the CDE official website showed that Iris vometinib mesylate tablets are planned to be included in the priority review and are intended for use with epidermal growth factor receptor (EGFR) exon 19 deletion mutations (19DEL) or First-line treatment for adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with exon 21 replacement mutation (21L858R) .
-
The State Food and Drug Administration released the 49th batch of generic drug reference preparation catalog
Time of Update: 2021-12-30
On December 8, the State Food and Drug Administration issued an announcement stating that the 49th batch of generic drug reference preparations catalogue was now released after the review and determination of the Expert Committee on the Quality and Efficacy Consistency Evaluation of Generic Drugs of the State Drug Administration .
-
More than 100 listed medical device companies disclosed the third quarter report of 2021: 12 revenue exceeded 5 billion yuan
Time of Update: 2021-12-30
Specifically, Mindray Medical's revenue and net profit in the first three quarters of 2021 achieved rapid growth compared with the same period in 2020, achieving operating income of 19.
-
Three local pharmaceutical companies move towards IPO, with a total fundraising of over 500 million U.S. dollars
Time of Update: 2021-12-30
According to the fixed increase draft, Northland's fixed increase financing will be used for drug research and development projects, bioengineering new drug industrialization projects and supplementary working capital, using the raised funds of 82.
-
Prevent new coronary pneumonia!
Time of Update: 2021-12-30
Author: Shi BeiOn December 8, AstraZeneca announced that the FDA had approved an emergency use authorization application for its long-acting antibody cocktail therapy Evusheld (tixagevimab+cilgavimab) for the prevention of SARS-CoV-2 before exposure .
-
In 2022, the wave of mergers and acquisitions of pharmaceutical companies is coming?
Time of Update: 2021-12-30
The purpose of continuous mergers and acquisitions by large pharmaceutical companies includes enhancing R&D pipelines, investing in blockbuster drugs under research or about to be launched, complementation of product portfolios and synergistic effects of scale, and so on .
-
Digital innovation sweeps the Chinese medicine industry, opening the journey of "intelligent manufacturing"
Time of Update: 2021-12-30
With the development and application of new technologies such as the Internet of Everything, big data, and artificial intelligence, digital innovation is also a tradition The Chinese medicine industry has brought more room for imagination .
-
Hengrui Medicine and Iktos of France reached a strategic cooperation on AI new drug R&D platform
Time of Update: 2021-12-30
According to the agreement, Hengrui will use Iktos' AI-based de novo drug design software Makya™ to accelerate the discovery of small molecule drugs and the optimization of lead compounds .
-
In order to accelerate innovation, local pharmaceutical companies still need to strengthen these aspects
Time of Update: 2021-12-30
However, it is worth noting that the industry believes that in addition to continuing to accelerate the development of domestic innovative drugs in the future; in terms of R&D management, pharmaceutical companies should also play the role of R&D managers to improve R&D capabilities, including basic research and targets.
-
Due to the increase in the price of raw materials, the price of this medicine has risen to 860 yuan
Time of Update: 2021-12-30
Recently, it has been reported that Beijing Tongrentang issued a price adjustment notice, raising the selling price of Angong Niuhuang Pills (3g*pills/box) from 780 yuan to 860 yuan, an increase of about 10%.
-
Centralized procurement of Chinese patent medicines is raging, and the industry: a wave of price cuts is inevitable
Time of Update: 2021-12-30
However, the recent developments of the 19-province alliance led by Hubei Province on the centralized procurement of Chinese patent medicines have attracted the attention of the industry.
The analysis believes that the plummet of Fusen Pharmaceutical may be related to the centralized procurement of Chinese patent medicines led by Hubei Province.
-
AI pharmacy has become an upsurge, and domestic and foreign pharmaceutical companies are vying for layout
Time of Update: 2021-12-30
. It is worth mentioning that, as pharmaceutical companies continue to increase their weight in AI pharmacy, some companies have made substantial breakthroughs in the research and development of new drugs .
-
Simcere's CDK4/6 inhibitor Trirazil is planned to be included in the priority review
Time of Update: 2021-12-30
Screenshot source: CDE official websiteThe proposed indication for Trilaciclib injection is the prophylactic use of Trilaciclib in patients with extensive stage small cell lung cancer (ES-SCLC) receiving platinum-containing drugs combined with etoposide to reduce bone marrow suppression caused by chemotherapy The rate of occurrence .
-
What is the problem of the recall of glass particles found in some of the new crown drug bottles in the United States?
Time of Update: 2021-12-30
Is the risk as big as we think?Recently, the FDA issued an announcement stating that some bottles of the new crown drug Remdesivir in the United States were found to contain glass particles.
